Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer-Reference-Cited by-同舟云学术

Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Published:2009-08-18 Issue:2 Volume:1 Page:69-77
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Dorff Tanya B.¹,Tangen Cathy M.²,Crawford E. David³,Petrylak Daniel P.⁴,Higano Celestia S.⁵,Raghavan Derek⁶,Quinn David I.⁷,Vogelzang Nicholas J.⁸,Thompson Ian M.⁹

Affiliation:

1. University of Michigan, Division of Hematology/ Oncology, 1500 E. Medical Center Dr., 7314 CCGC, Ann Arbor, MI 48109-0946, USA, , University of Southern California, Los Angeles, CA, USA

2. Southwest Oncology Group Statistical Center, Seattle, WA, USA

3. University of Colorado, Denver, CO, USA

4. Columbia University, New York, NY, USA

5. University of Washington, Seattle, WA, USA

6. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

7. University of Southern California, Los Angeles, CA, USA

8. Nevada Cancer Institute, Las Vegas, NV, USA

9. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Abstract

The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834009343454

Reference57 articles.

1. In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer

2. Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes

3. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer

4. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up

5. Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Hormone-Sensitive Metastatic Prostate Cancer;Hematology/Oncology Clinics of North America;2013-12

2. Non-castrate Metastatic Prostate Cancer: Have the Treatment Options Changed?;Seminars in Oncology;2013-06